Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) anticipates a profit of no less than RMB 20 million for the six months ending June 30, 2025, a significant turnaround from a loss of approximately RMB 44.9 million in the same period of 2024, driven by milestone revenues from three licensing collaborations and sales of commercialized products [1][1][1] Company Summary - Following the profit forecast announcement, Corning Jereh's stock rose over 3%, currently trading at HKD 9.42 with a transaction volume of HKD 10.1093 million [1][1][1] - The company possesses a robust proprietary technology platform in ADC (Antibody-Drug Conjugates), bispecific antibodies, and multifunctional protein engineering, with a highly differentiated internal pipeline covering anti-tumor drugs at various research and development stages [1][1][1] - Guangfa Securities expresses optimism regarding the company's differentiated biopolymer platform and the development potential of ADC drugs that have shown preliminary clinical efficacy [1][1][1]
港股异动 | 康宁杰瑞制药-B(09966)盈喜后涨超3% 预计中期利润不少于2000万元